Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Pancreatic Cancer Early Detection Consortium

NCT04970056 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.

Study Locations (20)

California

  • Providence Health and Services — Burbank
  • City of Hope — Duarte
  • UC San Diego Moores Cancer Center — La Jolla
  • Cedars-Sinai Medical Center — Los Angeles
  • UCLA Health — Los Angeles
  • Hoag — Newport Beach
  • UC Irvine Health — Orange
  • UC Davis — Sacramento
  • University of California, San Francisco (UCSF) — San Francisco

Florida

  • Mayo Clinic Jacksonville — Jacksonville
  • University of Miami — Miami
  • Moffitt Cancer Center — Tampa

Illinois

  • Illinois CancerCare — Bloomington
  • University of Chicago Medicine — Chicago
  • NorthShore University HealthSystem — Evanston

Arizona

  • Mayo Clinic Arizona — Phoenix
  • Honor Health Research Institute — Scottsdale

Connecticut

  • Yale University — New Haven

Georgia

  • Emory University Hospital — Atlanta

Kansas

  • University of Kansas Medical Center — Kansas City

Trial Details

FieldValue
Enrollment Target 20,000 participants
Start Date 2020-09-18
Est. Completion 2030-12-31

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04970056

The ClinicalTrials.gov registry entry for NCT04970056 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 20,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arbor Research Collaborative for Health, which has 8 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 4 conditions, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04970056 reports 20 study locations spanning 7 distinct geographic areas — top geographies include California, Florida, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04970056 about?

NCT04970056 is a clinical study titled "Pancreatic Cancer Early Detection Consortium". The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying ...

What is the current status of trial NCT04970056?

This trial is currently recruiting. The enrollment target is 20,000 participants. The study started on 2020-09-18. Estimated completion is 2030-12-31.

What conditions does trial NCT04970056 study?

This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma, Pancreas Cancer, Genetic Predisposition, Pancreas Cyst. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT04970056?

This trial is sponsored by Arbor Research Collaborative for Health, which has 8 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04970056 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial